DiaMedica Therapeutics Inc. (DMAC)
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$32.8M
- Total assets
- $61.4M
- Market cap
- $303.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $34.4M
- Operating income
- -$34.4M
- Income tax
- $28.0K
- Net income
- -$32.8M
- EPS (basic)
- $-0.70
Balance sheet
- Total assets
- $61.4M
- Current assets
- $60.6M
- Total liabilities
- $5.3M
- Current liabilities
- $5.1M
- Shareholders’ equity
- $56.1M
Cash flow
- Operating cash flow
- -$29.1M
- Investing cash flow
- -$2.2M
- Financing cash flow
- $43.9M
- Net cash flow
- $12.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $303.9M
- Shares outstanding
- 45.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 29, 2007
DiaMedica Therapeutics Inc. (DMAC) Stock Price
- Reported a net loss of $32.8M.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DiaMedica Therapeutics Inc..
Write a review
News about DiaMedica Therapeutics Inc.
News & sentiment via Polygon.io
DiaMedica Therapeutics Inc.: frequently asked questions
Is DiaMedica Therapeutics Inc. an American company?
DiaMedica Therapeutics Inc. is a US-based company headquartered in Minneapolis, Minnesota, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is DiaMedica Therapeutics Inc. headquartered?
DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota, United States.
Is DiaMedica Therapeutics Inc. publicly traded?
Yes — DiaMedica Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol DMAC on the NASDAQ.
What does DiaMedica Therapeutics Inc. do?
DiaMedica Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
